share_log

百利天恒(688506.SH):注射用BL-B01D1用于复发性或转移性食管鳞癌III期临床试验完成首例受试者入组

Baili Tianheng (688506.SH): BL-B01D1 for injection completed the first case of recurrent or metastatic esophageal squamous cell carcinoma phase III clinical trial

Gelonghui Finance ·  Apr 9 05:26

Gelonghui, April 9 | Bailey Tianheng (688506.SH) announced that the self-developed innovative biopharmaceutical injectable BL-B01D1 (EGFR×HER3-ADC) is currently undergoing phase III clinical trials for recurrent or metastatic esophageal squamous cell carcinoma, and has recently successfully completed the first case of the subject.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment